| For: | Kamrul-Hasan ABM, Borozan S, Jena S, Nagendra L, Dutta D, Bhattacharya S, Islam MS, Pappachan JM. Safety and efficacy of efruxifermin in metabolic dysfunction-associated steatohepatitis: A systematic review. World J Gastrointest Pharmacol Ther 2025; 16(3): 110709 [PMID: 40937291 DOI: 10.4292/wjgpt.v16.i3.110709] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v16/i3/110709.htm |
| Number | Citing Articles |
| 1 |
Yibin Cai, Jiayin Li, Shenyu Chen, Hui Zhang, Jie Tan, Hao Li, Shuyuan Zhang, Boran Li, Qin Wei, Chenshi Lin, Xuesong Zhong, Xiuhua You, Chao Qin, Chao Teng, Jie Liu. Liver fibrosis: Pathogenesis and innovative nanoparticle-based therapeutic strategies. International Journal of Pharmaceutics: X 2026; 12 doi: 10.1016/j.ijpx.2026.100596
|
| 2 |
Mohammadjavad Sotoudeheian. Untapped potential of efruxifermin in lean MASH. Hepatology International 2025; doi: 10.1007/s12072-025-10981-6
|
| 3 |
Doha Jaber, Inas Jaber, Ayah Abu Lehia, Thekrayat Asad, Hazem Ayesh. Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials. Endocrinology, Diabetes & Metabolism 2026; 9(3) doi: 10.1002/edm2.70218
|
| 4 |
Sakktivel Elangovan, Chang Chuen Mark Cheah, George Boon-Bee Goh. Incretin-based therapies: a new era in metabolic liver disease management. Hepatoma Research 2026; doi: 10.20517/2394-5079.2026.15
|
| 5 |
Rohit Loomba, Jacob George, Laurent Castera, Sven Francque, Eric Lawitz, Ahsan Shoeb, Jesper Ole Clausen, Birgitte Andersen, Anna Bille Larsen, Lise Lotte Gluud. Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial. The Lancet Gastroenterology & Hepatology 2026; doi: 10.1016/S2468-1253(26)00123-8
|